Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis

Table 2 Alternative splice variants selected for functional testing

	Splice variant	Clone	Length of ORF^a	Length of ECD^a	C-terminal novel amino acids^b
1	VEGFR1-541	018C02	541	758	LPPANSSFML PPTSFSSNYF HFLP*
2	VEGFR2-712	015F01	712	764	E*
3	VEGFR3-765	015G09	765	775	REGGPGEGQV RRPARPTIPN PGGPAPPPHP LQESTWRTPT RS*
4	Met-877	020H07	877	932	VRNALNTVLN HQLKLN*
5	Tie1-751	016G03	751	759	ERAGPTGPPG L*
6	CSF1R-306	005A06	306	512	GTPSPSLCPA *
7	c-Kit-413	002H01	413	520	SL*
8	PDGFRβ-336	007C09	336	531	RAATCGSWER WAHYNLLSCI GAGHCR*
9	FGFR1-320	022C02	320	374	GTHCNFSSRC PALATGTGGA CISRLGETQR QESWKNGLLP AWCHILPQL*
10	RAGE-387	021C06	387	342	IGETSPQALQ TLGLGCRTAQ ALISCPILAL SLTATPPLPP CTHTQASPAP PAFCQESSQA SPFFPLS*

Ten alternative splice variants were selected for functional testing. ^aLengths of the alternative splice variant open-reading frames (ORF) and lengths of the wildtype receptor extracellular domains (ECD) are indicated by the numbers of amino acids. ^bNovel C-terminal amino acids of each alternative splice variant are shown. *Stop codon.